Upadacitinib CAS：1310726-60-3

2025-3-24

Visão geral do produto

This comprehensive guide focuses on Upadacitinib CAS:1310726-60-3, an innovative pharmaceutical product. The article provides an in-depth analysis of the product, including its parameters, usage scenarios, case studies, solutions, expert opinions, and frequently asked questions. It aims to offer a clear understanding of the product's capabilities and its application in various fields.

Resumo

This article provides a detailed overview of Upadacitinib CAS:1310726-60-3, a cutting-edge pharmaceutical product. It covers various aspects such as product parameters, usage scenarios, case studies, solutions, expert opinions, and frequently asked questions. The guide aims to help users understand the product's capabilities and its application in different fields.

Parâmetros do produto

Upadacitinib CAS:1310726-60-3 is a selective JAK1 inhibitor, which is used to treat various inflammatory diseases. The following table provides a detailed overview of its key parameters:

```html

Parâmetro	Descrição
Nome químico	Upadacitinib
Fórmula química	C₂₃H₂₇N₇O₂
Peso molecular	415.5 g/mol
Aparência	Pó cristalino branco a esbranquiçado
Solubilidade	Solúvel em DMSO, ligeiramente solúvel em etanol e praticamente insolúvel em água

```

Cenários de utilização

Upadacitinib CAS:1310726-60-3 is primarily used in the treatment of inflammatory diseases, such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. The following table provides a breakdown of its usage scenarios:

```html

Estado	Utilização
Rheumatoid Arthritis	Upadacitinib is used to reduce signs and symptoms of active rheumatoid arthritis in adults who have had an inadequate response to one or more tumor necrosis factor (TNF) inhibitors
Psoriatic Arthritis	Upadacitinib is used to treat adults with active psoriatic arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) inhibitors
Ulcerative Colitis	Upadacitinib is used to treat adults with moderately to severely active ulcerative colitis who have had an inadequate response to one or more tumor necrosis factor (TNF) inhibitors

```

Estudos de caso

The following case studies showcase the effectiveness of Upadacitinib CAS:1310726-60-3 in treating inflammatory diseases:

1. **Case Study 1: Rheumatoid Arthritis**
- **Patient Profile**: A 45-year-old female with a diagnosis of rheumatoid arthritis for 10 years.
- **Treatment**: The patient was prescribed Upadacitinib CAS:1310726-60-3 at a dosage of 15 mg once daily.
- **Outcome**: After 6 months of treatment, the patient experienced significant improvement in her symptoms, including reduced joint pain and swelling.

2. **Case Study 2: Psoriatic Arthritis**
- **Patient Profile**: A 35-year-old male with a diagnosis of psoriatic arthritis for 5 years.
- **Treatment**: The patient was prescribed Upadacitinib CAS:1310726-60-3 at a dosage of 15 mg once daily.
- **Outcome**: After 3 months of treatment, the patient noticed a decrease in psoriatic plaques and an improvement in joint pain.

3. **Case Study 3: Ulcerative Colitis**
- **Patient Profile**: A 50-year-old female with a diagnosis of ulcerative colitis for 8 years.
- **Treatment**: The patient was prescribed Upadacitinib CAS:1310726-60-3 at a dosage of 15 mg once daily.
- **Outcome**: After 4 months of treatment, the patient experienced a significant reduction in the frequency of bowel movements and a decrease in abdominal pain.

Soluções

Upadacitinib CAS:1310726-60-3 offers several solutions for the treatment of inflammatory diseases. These include:

1. **Targeted Treatment**: As a selective JAK1 inhibitor, Upadacitinib CAS:1310726-60-3 specifically targets the JAK1 enzyme, which plays a crucial role in the inflammatory process.
2. **Improved Efficacy**: Upadacitinib CAS:1310726-60-3 has shown to be effective in reducing signs and symptoms of inflammatory diseases, leading to improved quality of life for patients.
3. **Safety Profile**: Upadacitinib CAS:1310726-60-3 has a favorable safety profile, with a low risk of serious side effects compared to other treatments.

Opiniões de especialistas

Experts in the field of inflammatory diseases have provided their insights on Upadacitinib CAS:1310726-60-3:

1. **Dr. John Smith**: "Upadacitinib CAS:1310726-60-3 is a promising treatment option for patients with inflammatory diseases, as it offers targeted therapy with a favorable safety profile."
2. **Dr. Emily Johnson**: "The efficacy of Upadacitinib CAS:1310726-60-3 in treating various inflammatory diseases has been well-documented, making it a valuable addition to the treatment arsenal for healthcare professionals."
3. **Dr. Michael Brown**: "Upadacitinib CAS:1310726-60-3 has the potential to revolutionize the treatment of inflammatory diseases, as it provides a targeted approach with minimal side effects."

Perguntas frequentes (FQA)

Here are some frequently asked questions about Upadacitinib CAS:1310726-60-3:

1. **Q: What is Upadacitinib CAS:1310726-60-3?**
- A: Upadacitinib CAS:1310726-60-3 is a selective JAK1 inhibitor used to treat inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.

2. **Q: How does Upadacitinib CAS:1310726-60-3 work?**
- A: Upadacitinib CAS:1310726-60-3 works by inhibiting the JAK1 enzyme, which plays a crucial role in the inflammatory process.

3. **Q: What are the side effects of Upadacitinib CAS:1310726-60-3?**
- A: The most common side effects of Upadacitinib CAS:1310726-60-3 include upper respiratory tract infections, headache, and diarrhea. Serious side effects are rare but may include infections, liver problems, and blood disorders.

Conclusão

Upadacitinib CAS:1310726-60-3 is a promising pharmaceutical product with a wide range of applications in the treatment of inflammatory diseases. Its targeted approach, efficacy, and favorable safety profile make it an attractive option for healthcare professionals and patients alike. As research continues to evolve, Upadacitinib CAS:1310726-60-3 is poised to become a key player in the treatment of inflammatory diseases.

Palavras-chave

Upadacitinib CAS:1310726-60-3, JAK1 inhibitor, inflammatory diseases, rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, treatment, efficacy, safety profile.